Mizuho Initiates Coverage On Spyre Therapeutics with Outperform Rating, Announces Price Target of $53

Benzinga · 2d ago
Mizuho analyst Joseph Catanzaro initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Outperform rating and announces Price Target of $53.